Progress in Neurobiology: Pathogenic Oligomeric Tau alters Neuronal RNA Processes through the Formation of Nuclear Heteromeric Amyloids with RNA-Binding Protein Musashi1 (Penalva)

March 11, 2025

 Nicha Puangmalai a b 1, Abbigael E. Aday a b 1, Madison Samples a b, Nemil Bhatt a b, Filippa Lo Cascio a b, Michela Marcatti a b, Suhyeorn J. Park a b, Leiana Fung a b, Cynthia Jerez a b, Luiz O. Penalva c d, Yingxin Zhao e, Haiping Hao f, Doreen Lugano g, Rakez Kayed a b, Mauro Montalbano a b Abstract Alzheimer’s disease (AD) is marked by cytoplasmic proteinopathies, primarily involving misfolded Tau protein. Pathogenic Tau species, such as soluble oligomers and fibrils, disrupt RNA metabolism, though the mechanisms are unclear. Recent research indicates that RNA has a crucial role in Tau aggregation. Our study builds on this by noting [...]

ELife: SERBP1 interacts with PARP1 and is present in PARylation-dependent protein complexes regulating splicing, cell division, and ribosome biogenesis (Libich, Penalva, et al)

February 13, 2025

 Kira Breunig#1, Xuifen Lei#1, Mauro Montalbano#23, Gabriela D A Guardia4, Shiva Ostadrahimi15, Victoria Alers156, Adam Kosti15, Jennifer Chiou7, Nicole Klein1, Corina Vinarov1, Lily Wang1, Mujia Li1, Weidan Song8, W Lee Kraus8, David S Libich16, Stefano Tiziani7910, Susan T Weintraub6, Pedro A F Galante4, Luiz O Penalva15 Abstract RNA binding proteins (RBPs) containing intrinsically disordered regions (IDRs) are present in diverse molecular complexes where they function as dynamic regulators. Their characteristics promote liquid-liquid phase [...]

Cell: Fine-tuning of gene expression through the Mettl3-Mettl14-Dnmt1 axis controls ESC differentiation (Gupta Lab)

January 17, 2025

 Giuseppe Quarto1,12 ∙ Andrea Li Greci1,12 ∙ Martin Bizet1,12 ∙ Audrey Penning1 ∙ Irina Primac1 ∙ Frédéric Murisier1 ∙ Liliana Garcia-Martinez2 ∙ Rodrigo L. Borges2 ∙ Qingzeng Gao3,4 ∙ Pradeep K.R. Cingaram2 ∙ Emilie Calonne1 ∙ Bouchra Hassabi1 ∙ Céline Hubert1 ∙ Adèle Herpoel1 ∙ Pascale Putmans1 ∙ Frédérique Mies1 ∙ Jérôme Martin1 ∙ Louis [...]

International Journal of Molecular Sciences: Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination Therapy (Penalva)

January 16, 2025

 Jennifer Chiou Valeria Impedovo Yen Bao Huynh ,Ruggiero Gorgoglione Luiz O. F. Penalva Alessia Lodi Andrew J. Brenner Stefano Tiziani Abstract Glioblastoma (GBM), the most prevalent primary malignant brain tumor, remains challenging to treat due to extensive inter- and intra-tumor heterogeneity. This variability demands combination treatments to improve therapeutic outcomes. A significant obstacle in treating [...]

Aging Cell: Age-Dependent Bi-Phasic Dynamics of Ly49+CD8+ Regulatory T Cell Population (Rao)

December 19, 2024

Saranya Srinivasan, Shruti Mishra, Kenneth Ka-Ho Fan, Liwen Wang, John Im, Courtney Segura, Neelam Mukherjee, Gang Huang, Manjeet Rao, Chaoyu Ma, Nu Zhang ABSTRACT Aging is tightly associated with reduced immune protection but increased risk of autoimmunity and inflammatory conditions. Regulatory T cells are one of the key cells to maintaining immune homeostasis. The age-dependent changes in CD4+Foxp3+ regulatory T cells (Tregs) have been well […]

Clinical Cancer Research: Update on Surveillance for Wilms Tumor and Hepatoblastoma in Beckwith–Wiedemann Syndrome and Other Predisposition Syndromes (Tomlinson)

December 2, 2024

 Update on Surveillance for Wilms Tumor and Hepatoblastoma in Beckwith–Wiedemann Syndrome and Other Predisposition Syndromes Jennifer M. Kalish Kerri D. Becktell Gaëlle Bougeard Garrett M. Brodeur Lisa R. Diller Andrea S. Doria Jordan R. Hansford Steven D. Klein Wendy K. Kohlmann Christian P. Kratz Suzanne P. MacFarland Kristian W. Pajtler Surya P. Rednam Jaclyn Schienda [...]

SLAS Discovery: The History, Landscape, and Outlook of Human Cell Line Authentication and Security (Pertsemlidis)

November 20, 2024

 Elijah Harbut1,2,3 ∙ Yiorgos Makris4 ∙ Alexander Pertsemlidis5,6,7 ∙ Leonidas Bleris1,2,3 1 Introduction The phenomenon of cellular cross-contamination and misidentification (“CCCM”) was identified more than six decades ago and continues to pose significant challenges for laboratories globally. The prevalence of CCCM is alarmingly high, with estimates suggesting that up to 30% of cell lines may be misidentified, leading to substantial financial losses[2–4]. Accelerating progress in [...]

Molecular Cancer Therapeutics: Abstract B016: RNA demethylase ALKBH5 drives medulloblastoma growth and progression (Rao, Chen, Gupta, & Houghton Labs)

November 18, 2024

 Panneerdoss Subbarayalu; Daisy Medina; Pitta Prabhakar; Shahad Abdulsahib; Saif Nirzhor; Desiree Denman; Santosh Timilsina; Deepika Singh; Phat Do; Krishna Evani; Dhiya Billa; Esha Reddy; Peter Houghton; Yogesh Gupta; Yidong Chen; Suryavathi Viswanadhapalli; Ratna Vadlamudi; Andrew Brenner; Manjeet Rao Abstract Introduction: Medulloblastoma (MB) is the most common malignant childhood brain tumor. It accounts for 20% of [...]

Pharmacology & Therapeutics: Lessons learned from 20 years of preclinical testing in pediatric cancers (Houghton, Kurmasheva)

November 11, 2024

 Malcolm A. Smith a, Peter J. Houghton b, Richard B. Lock c, John M. Maris d, Richard Gorlick e, Raushan T. Kurmasheva b, Xiao-Nan Li f, Beverly A. Teicher a, Jeffrey H. Chuang g, Filemon S. Dela Cruz h, Michael A. Dyer i, Andrew L. Kung h, Michael W. Lloyd j, Yael P. Mosse d, Timothy M. Stearns j, Elizabeth A. Stewart i, Carol J. Bult j, Stephen W. Erickson k   Abstract Programs for preclinical testing of targeted cancer agents in murine models of childhood cancers have been supported by the National Cancer Institute (NCI) since 2004. These programs were established to work collaboratively with industry partners [...]